Skin, hair & tissue science
AHK-Cu
Cell/laboratory researchAHK-Cu combines alanine-histidine-lysine with copper. It differs from GHK-Cu by one amino acid. Its hair-related reputation rests substantially on laboratory studies.
Source review: September 9, 2026. Scientific evidence and trial records change over time.
01 · What is it?
The identity comes first.
AHK-Cu combines alanine-histidine-lysine with copper. It differs from GHK-Cu by one amino acid. Its hair-related reputation rests substantially on laboratory studies.
Scientific classification: Copper-binding tripeptide complex
For example. Changing one letter can change a word; changing glycine to alanine can change a peptide’s properties.
02 · How does it work?
The signal, explained.
Experiments expose hair-follicle-related cells to the copper-peptide complex and measure growth or survival responses. The first molecular step behind those responses remains uncertain.
The key research focus is Dermal papilla cell responses; no established unique receptor. A target describes where an interaction may occur; it does not by itself establish a benefit.
Learn the Science · mechanism
Cultured dermal papilla cells and isolated human follicles have been studied for proliferation and survival responses to AHK-Cu. The exact initiating target remains incompletely established.
03 · What happens after the signal?
Follow the downstream effects.
Changes in cell proliferation and apoptosis-related markers may influence follicle behavior in culture. Follicle elongation outside the body does not establish scalp hair regrowth in people.
To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.
04 · What is it commonly researched for?
The questions researchers are asking.
Scientists have studied human hair-follicle growth in vitro and dermal papilla cell biology.
These are areas of investigation, not promises about a Maison product.
05 · Body systems involved
Where the biology connects.
- Skin
- Includes barrier tissue, fibroblasts and hair follicles where applicable; cell findings are not automatically clinical outcomes.
06 · Receptor / target profile
The molecular reference card.
- Primary receptor or target
- Dermal papilla cell responses; no established unique receptor
- Secondary interactions
- No additional primary target established for the research claim discussed.
- Where it is found
- Skin
- Activation, inhibition or interaction
- Cultured dermal papilla cells and isolated human follicles have been studied for proliferation and survival responses to AHK-Cu. The exact initiating target remains incompletely established.
- Important downstream pathways
- Changes in cell proliferation and apoptosis-related markers may influence follicle behavior in culture. Follicle elongation outside the body does not establish scalp hair regrowth in people.
07 · Evidence quality
What carries weight—and what does not.
STRONGER EVIDENCE
Convincing replicated human evidence for the broad wellness claims is not established.
EMERGING HUMAN EVIDENCE
Human outcome evidence remains limited for this exact form and proposed use.
EARLY / PRECLINICAL EVIDENCE
The cited human follicle experiment is laboratory research, not a trial involving human participants.
UNKNOWN OR NOT WELL ESTABLISHED
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.
08 · Who is studying it?
Follow the original research.
No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.
Regulatory context: No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
VIEW CURRENT CLINICAL TRIALSRegistry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.
09 · Research terminology
A small glossary for this page.
Target
The molecule or biological structure a compound interacts with.
Pathway
A sequence of cellular events connecting a signal to a response.
Preclinical
Research outside human clinical trials, including cells and animals.
apoptosis
A regulated process of cell death. Preventing it is not automatically beneficial in every setting.
Biomarker
A measurable biological feature. A change in a marker does not always translate into a meaningful health outcome.
Target engagement
Evidence that a compound actually reaches and interacts with the intended biological target.
Randomized controlled trial
A study that assigns participants by chance to comparison groups, helping separate an intervention’s effects from other influences.
10 · Research status & limitations
Keep the boundaries visible.
No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.
Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.
The main evidence category here is cell/laboratory research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.
11 · References / continue reading
Go to the source.
Individual study links support the associated research discussion. Literature-search links are clearly labelled and help you explore further; they are not themselves proof of a claim. Sponsor announcements should be read alongside published papers and current regulatory records.